Insulin-like growth factor-I and breast cancer therapy

Yasir H. Ibrahim, Douglas Yee, Kent Osborne, Stephen Johnston, Carlos Arteaga, Richard Santen

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Targeting hormonal and growth factor signaling pathways has proven to be useful in the treatment of breast cancer. In vitro, animal, and epidemiologic evidence provide a rationale for the relevance of the insulin-like growth factor (IGF) system to breast cancer biology. The IGF system has been implicated in promoting mitogenic, metastatic, and antiapoptotic phenotypes in breast cancer. As a consequence of the ability of IGF to promote tamorigenesis, pharmacologic interventions targeting the IGF system are being devised. Such strategies include decreasing ligand production, ligand binding, or receptor activation. In this article, directed anti-IGF strategies and the possible clinical impact of using such therapies for treating breast cancer are discussed.

Original languageEnglish (US)
JournalClinical Cancer Research
Volume11
Issue number2 II
StatePublished - Jan 15 2005

Fingerprint

Somatomedins
Insulin-Like Growth Factor I
Breast Neoplasms
Ligands
Therapeutics
Intercellular Signaling Peptides and Proteins
Phenotype

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ibrahim, Y. H., Yee, D., Osborne, K., Johnston, S., Arteaga, C., & Santen, R. (2005). Insulin-like growth factor-I and breast cancer therapy. Clinical Cancer Research, 11(2 II).

Insulin-like growth factor-I and breast cancer therapy. / Ibrahim, Yasir H.; Yee, Douglas; Osborne, Kent; Johnston, Stephen; Arteaga, Carlos; Santen, Richard.

In: Clinical Cancer Research, Vol. 11, No. 2 II, 15.01.2005.

Research output: Contribution to journalArticle

Ibrahim, YH, Yee, D, Osborne, K, Johnston, S, Arteaga, C & Santen, R 2005, 'Insulin-like growth factor-I and breast cancer therapy', Clinical Cancer Research, vol. 11, no. 2 II.
Ibrahim YH, Yee D, Osborne K, Johnston S, Arteaga C, Santen R. Insulin-like growth factor-I and breast cancer therapy. Clinical Cancer Research. 2005 Jan 15;11(2 II).
Ibrahim, Yasir H. ; Yee, Douglas ; Osborne, Kent ; Johnston, Stephen ; Arteaga, Carlos ; Santen, Richard. / Insulin-like growth factor-I and breast cancer therapy. In: Clinical Cancer Research. 2005 ; Vol. 11, No. 2 II.
@article{7971b48a60b940de8f1ec663db7c1379,
title = "Insulin-like growth factor-I and breast cancer therapy",
abstract = "Targeting hormonal and growth factor signaling pathways has proven to be useful in the treatment of breast cancer. In vitro, animal, and epidemiologic evidence provide a rationale for the relevance of the insulin-like growth factor (IGF) system to breast cancer biology. The IGF system has been implicated in promoting mitogenic, metastatic, and antiapoptotic phenotypes in breast cancer. As a consequence of the ability of IGF to promote tamorigenesis, pharmacologic interventions targeting the IGF system are being devised. Such strategies include decreasing ligand production, ligand binding, or receptor activation. In this article, directed anti-IGF strategies and the possible clinical impact of using such therapies for treating breast cancer are discussed.",
author = "Ibrahim, {Yasir H.} and Douglas Yee and Kent Osborne and Stephen Johnston and Carlos Arteaga and Richard Santen",
year = "2005",
month = "1",
day = "15",
language = "English (US)",
volume = "11",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "2 II",

}

TY - JOUR

T1 - Insulin-like growth factor-I and breast cancer therapy

AU - Ibrahim, Yasir H.

AU - Yee, Douglas

AU - Osborne, Kent

AU - Johnston, Stephen

AU - Arteaga, Carlos

AU - Santen, Richard

PY - 2005/1/15

Y1 - 2005/1/15

N2 - Targeting hormonal and growth factor signaling pathways has proven to be useful in the treatment of breast cancer. In vitro, animal, and epidemiologic evidence provide a rationale for the relevance of the insulin-like growth factor (IGF) system to breast cancer biology. The IGF system has been implicated in promoting mitogenic, metastatic, and antiapoptotic phenotypes in breast cancer. As a consequence of the ability of IGF to promote tamorigenesis, pharmacologic interventions targeting the IGF system are being devised. Such strategies include decreasing ligand production, ligand binding, or receptor activation. In this article, directed anti-IGF strategies and the possible clinical impact of using such therapies for treating breast cancer are discussed.

AB - Targeting hormonal and growth factor signaling pathways has proven to be useful in the treatment of breast cancer. In vitro, animal, and epidemiologic evidence provide a rationale for the relevance of the insulin-like growth factor (IGF) system to breast cancer biology. The IGF system has been implicated in promoting mitogenic, metastatic, and antiapoptotic phenotypes in breast cancer. As a consequence of the ability of IGF to promote tamorigenesis, pharmacologic interventions targeting the IGF system are being devised. Such strategies include decreasing ligand production, ligand binding, or receptor activation. In this article, directed anti-IGF strategies and the possible clinical impact of using such therapies for treating breast cancer are discussed.

UR - http://www.scopus.com/inward/record.url?scp=12144277344&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12144277344&partnerID=8YFLogxK

M3 - Article

VL - 11

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 2 II

ER -